Babson Diagnostics Raises $31 Million In Series B Funding To Drive Retailization Of Customer-First, Convenient, And Highly Accessible Diagnostic Blood Testing
Babson Diagnostics Raises $31 Million In Series B Funding To Drive Retailization Of Customer-First, Convenient, And Highly Accessible Diagnostic Blood Testing
06/29/21, 12:08 PM
Location
austinMoney raised
$31 million
Round Type
series b
Babson Diagnostics, a transformative medical technology company improving customer access to diagnostic blood testing, today announced the closing of $31 million in an oversubscribed Series B funding round, led by Emerald Development Managers, with full participation by existing investors Siemens Healthineers, Prism Ventures, and Lago Consulting Group.
Company Info
Location
austin, texas, united states
Additional Info
Babson Diagnostics aims to democratize diagnostic blood testing by making it easier, faster, and more pleasant for customers to routinely monitor and improve their health. Babson's proprietary technological ecosystem is designed to deliver accurate diagnostic results with a more human experience. Based in Austin, Texas, its vision for diagnostic blood testing — built on accuracy, convenience, and accessibility — combines transformative diagnostic technology with a customer-first, retail-centric business model that aims to improve customer health and experience. Prior to commercialization, Babson Diagnostics is working with retail pharmacies to validate its technology by conducting clinical studies intended for peer-reviewed publication. For more information on Babson Diagnostics, please visit www.babsondx.com.